Lesiones de la válvula aórtica

  1. Longás Tejero, M.A.
  2. Santa Cruz Hernández, J.
  3. Guerra Torres, X.E.
  4. Araoz Illanes, R.
  5. García Lledó, A.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Serie: 12

Número: 40

Páginas: 2357-2369

Tipo: Artículo

DOI: 10.1016/J.MED.2017.09.002 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Abstract : presently, the most frequent cause of AS is the related to age degenerative calcificated AS. transthoracic echocardiography is the key diagnostic tool, also for follow-up. Other useful diagnostic techniques are basal EKG, exercise and Dobutamine stress ecocardiography, transesophageal echocardiography, exercise stress testing, multi-slice CT and cardiac MR, natriuretic peptides and cardiac catheterization. we must intervene on patients with symptomatic severe AS, mainly by surgical aortic valve replacement, and if surgical risk is very high, TAVI can be a suitable alternative. it can be caused by aortic valve and/or aortic root primary disease. transthoracic echocardiography is the key diagnostic tool too, also for follow-up. Other useful diagnostic techniques are basal EKG, transesophageal echocardiography, multi-slice TC and cardiac MR, exercise stress testing and cardiac catheterization. severe acute AR must be urgently operated. In chronic severe AR, when symptoms and/or left ventricular systolic dysfunction appear, we must undertake aortic valve surgery. Sometimes, it is necessary to perform surgery on aortic root an ascending aorta, and it will be performed whatever the severity of AR.

Referencias bibliográficas

  • Otto CM, Bonow RO. Valvular heart disease. Braunwald’s heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 1625-712.
  • Tornos Mas P, Sitges Carreño M. Valvulopatías. Farreras-Rozman: Medicina Interna. 19ª ed. (eds.). Barcelona: Elsevier España; 2016. p. 508-13.
  • O ́Gara PT, Loscalzo J. Valvulopatía aórtica. Harrison: Principios de Medicina Interna, 19th ed. México, D.F.: McGraw-Hill Interamericana; 2016. p. 1528-38.
  • Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disesase of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42:S1-S44.
  • Iung B, Barón G, Butchart EG, Delahaye F, Gohike-Bärwolf C, Levang OW. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231-43.
  • Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enríquez-Sarano M. Burden of valvular heart disease: a population-based study. Lancet. 2006;368:1005-11.
  • Levy F, Laurent M, Monin J, Maillet JM, Pasquet A, Le Tourneau T. Aortic valve replacement for low-flow / low-gradient aortic stenosis, operative risk stratification and long term outcome: a European multicenter study. J Am Coll Cardiol. 2008;51:1466-72.
  • Di Pasquale G, Coutsoumbas GV, Zagnoni S. Severe low gradient aortic stenosis, with preserved ventricular function: should it be treated? J Cardiovasc Med. 2017;18Suppl1:e105-11.
  • Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-14.
Fuente de los datos: Dialnet